http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102784105-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5456846495c5fa8a02f5eaae9faae290 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2012-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f66309e5b9852a58d6b7792ca1ffbb25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c2a2a2d634d74d2140f5fb817533327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c99a1244b762e79270f3191e3e6bf6d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf96bfce34ea1fea1f09756f34ac5d29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c9655933a631be3caa4ced6a33d3590 |
| publicationDate | 2014-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102784105-B |
| titleOfInvention | RLT polypeptide-mediated docetaxel tumor targeting submicroemulsion and preparation method thereof |
| abstract | The invention relates to a polypeptide (RLT polypeptide)-mediated docetaxel tumor targeting submicroemulsion combined with a low density lipoprotein binding domain in an apolipoprotein B, and a preparation method thereof, which belong to the medical technology field. The submicroemulsion is the tumor targeting submicroemulsion prepared from oil for injection, emulsifying agents, auxiliary emulsifying agents, antioxygen, isoosmotic adjusting agents, bi-stearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, RLT polypeptide and docetaxel. The weight volume concentration range of the docetaxel is 0.5-20mg/mL. The tumor targeting submicroemulsion has uniform grain size, and the average grain size is 182nm. The docetaxel submicroemulsion is modified by tumor targeting cells, so that the tumor targeting efficiency is obviously improved, the distribution of medicine in the tumor cells is increased, and other normal medicine dose is reduced. Therefore, due to the RLT polypeptide-mediated docetaxel tumor targeting submicroemulsion, the therapeutic effect of the medicine can be improved, and the toxic and side effects are reduced. |
| priorityDate | 2012-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.